TRIM63

TRIM63 (MuRF-1) is a striated muscle-specific RING-finger E3 ubiquitin ligase that anchors to the sarcomere M-line through high-affinity binding of its C-terminal helical domain to titin A168-A170 modules, where it ubiquitinates myofibrillar substrates—including troponin-I, myosin light chain 2, and titin—to drive proteasomal degradation during skeletal muscle atrophy (PMID:15967462, PMID:17215480, PMID:32933049). Beyond proteasomal targeting, TRIM63 promotes selective autophagy of nicotinic acetylcholine receptors at the neuromuscular junction through a pathway involving SQSTM1 and SH3GLB1, and its transcription is synergistically activated by FoxO3 and SMAD3 via a conserved FRE-SBE motif in the proximal promoter (PMID:24220501, PMID:24920680). Biallelic loss-of-function variants in TRIM63 cause autosomal-recessive hypertrophic cardiomyopathy with concentric left ventricular hypertrophy (PMID:32451364).

1. 2001 Medium

   Initial identification of TRIM63 as a striated-muscle-restricted RING finger protein that interacts with SUMO-2 via its RING domain established this gene as a potential signaling node in muscle, though its enzymatic activity was not yet defined.

   Evidence Yeast two-hybrid and RING domain mutagenesis in C2C12 myoblasts

   PMID:11283016

   Open questions at the time

   • SUMO-2 interaction not confirmed by reciprocal pull-down or in vivo assay
   • E3 ligase activity not yet demonstrated
   • Nuclear localization seen only in transiently transfected myoblasts, not endogenous protein
2. 2005 High

   Systematic mapping of TRIM63 substrates revealed it interacts with and ubiquitinates key myofibrillar proteins (troponin-I, MLC-2) and metabolic enzymes, establishing it as an E3 ligase that targets both structural and metabolic components of the sarcomere.

   Evidence Yeast two-hybrid screen of skeletal muscle cDNA library combined with Western blot analysis of MuRF-1 knockout mice showing reduced substrate ubiquitination

   PMID:15967462

   Open questions at the time

   • In vitro reconstituted ubiquitination assays for each individual substrate not performed in this study
   • Relative contribution of each substrate to atrophy phenotype unknown
3. 2007 High

   Crystal structure of the titin A168-A170 region and biophysical binding studies revealed how TRIM63 is physically recruited to the sarcomere M-line via a shallow surface groove on titin, providing a structural basis for localized substrate ubiquitination.

   Evidence X-ray crystallography, isothermal calorimetry, and pull-down assays

   PMID:17215480

   Open questions at the time

   • No structure of the TRIM63 C-terminal helical domain itself or the full complex
   • Whether titin binding is required for substrate ubiquitination in vivo not tested
4. 2013 High

   Discovery that TRIM63 drives selective autophagy of nicotinic acetylcholine receptors at the neuromuscular junction via SQSTM1 and SH3GLB1 expanded its role beyond proteasomal degradation to include autophagic membrane receptor turnover.

   Evidence Trim63 knockout mice with denervation, immunofluorescence colocalization, and comparison with ATG7 knockout

   PMID:24220501

   Open questions at the time

   • Whether TRIM63 directly ubiquitinates CHRN subunits or acts indirectly through SQSTM1 not resolved
   • Mechanism linking TRIM63 RING activity to autophagosome formation not defined
5. 2014 High

   Identification of synergistic FoxO3-SMAD3 co-regulation of TRIM63 transcription through a conserved FRE-SBE promoter element explained how TGF-β and insulin/Akt pathways converge to control atrophy gene expression.

   Evidence ChIP, promoter-reporter mutagenesis, and SMAD3 DNA-binding mutant analysis in cultured myotubes

   PMID:24920680

   Open questions at the time

   • In vivo validation of SBE requirement for TRIM63 induction during atrophy not performed
   • Other transcription factors contributing to TRIM63 regulation not systematically explored
6. 2020 Medium

   Large-cohort human genetic studies established that biallelic TRIM63 loss-of-function causes autosomal-recessive hypertrophic cardiomyopathy, revealing a non-redundant cardioprotective role distinct from its skeletal muscle atrophy function.

   Evidence Next-generation sequencing of 4867 HCM index cases with familial segregation analysis

   PMID:32451364

   Open questions at the time

   • No functional rescue or in vitro mechanistic follow-up of identified variants
   • Cardiac-specific substrates whose accumulation drives HCM not identified
   • Relationship between heterozygous carrier status and subclinical phenotypes not explored

• The mechanism by which TRIM63 loss leads to hypertrophic cardiomyopathy—specifically which cardiac substrates accumulate and whether proteasomal or autophagic pathways are impaired—remains undefined.
• No cardiac-specific substrate identification for TRIM63
• No structural model of full-length TRIM63 or TRIM63-substrate complexes
• Whether TRIM63 autophagic and proteasomal functions are independently regulated is unknown